全球胚胎着床前基因检测市场规模、份额、趋势和成长分析报告（2026-2034年）

预计胚胎着床前基因检测 (PGD) 市场将从 2025 年的 1021510000 美元增长到 2034 年的 2587760000 美元，2026 年至 2034 年的复合年增长率为 10.88%。

随着辅助生殖技术的进步和广泛应用，全球胚胎胚胎着床前遗传学检测（PGT）市场正在快速成长。 PGT用于体外受精（IVF）过程中，在胚胎胚胎着床前胚胎着床前筛检是否有遗传异常。这一过程有助于提高妊娠成功率并降低遗传疾病的风险。

该市场的主要驱动因素是全球遗传疾病和不孕症问题日益增加。随着人们对基因筛检的认识不断提高，越来越多的患者选择先进的辅助生殖技术。此外，基因测序和基因分析技术的进步也提高了胚胎植入前遗传学筛检（PGT）的准确性和可靠性。

未来，随着生殖医学的进步，胚胎着床前遗传学检测（PGT）市场预计将显着成长。对个人化生殖医学日益增长的需求以及体外受精成功率的提高将推动市场成长。遗传学和生殖生物学领域的持续研究也可能为先进的胚胎筛检技术创造新的机会。

目录

第一章：引言

第二章执行摘要

第三章 市场变数、趋势与框架

• 市场谱系展望
• 渗透率和成长前景分析
• 价值链分析
• 法律规范
  • 标准与合规性
  • 监管影响分析
• 市场动态
  • 市场驱动因素
  • 市场限制因素
  • 市场机会
  • 市场挑战
• 波特五力分析
• PESTLE分析

第四章：全球胚胎着床前基因检测市场：依类型划分

• 市场分析、洞察与预测
• 染色体异常
• 非整倍体
• X连锁疾病
• 单基因疾病
• HLA型检测
• 性别选择
• 其他的

第五章 全球胚胎着床前基因检测市场：依最终用户划分

• 市场分析、洞察与预测
• 诊断检查室
• 医院
• 诊所
• 其他的

第六章 全球胚胎着床前基因检测市场：依地区划分

• 区域分析
• 北美市场分析、洞察与预测
  • 我们
  • 加拿大
  • 墨西哥
• 欧洲市场分析、洞察与预测
  • 英国
  • 法国
  • 德国
  • 义大利
  • 俄罗斯
  • 其他欧洲国家
• 亚太市场分析、洞察与预测
  • 印度
  • 日本
  • 韩国
  • 澳洲
  • 东南亚
  • 其他亚太国家
• 拉丁美洲市场分析、洞察与预测
  • 巴西
  • 阿根廷
  • 秘鲁
  • 智利
  • 其他拉丁美洲国家
• 中东和非洲市场分析、洞察与预测
  • 沙乌地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中东和非洲国家

第七章 竞争情势

• 最新趋势
• 公司分类
• 供应链和销售管道合作伙伴（根据现有资讯）
• 市场占有率和市场定位分析（基于现有资讯）
• 供应商情况（基于现有资讯）
• 策略规划

第八章：公司简介

• 主要公司的市占率分析
• 公司简介
  • Illumina Inc
  • Thermo Fisher Scientific Inc
  • Agilent Technologies Inc
  • PerkinElmer Inc
  • CooperSurgical Inc
  • Abbott Laboratories
  • Natera Inc
  • Takara Bio
  • Oxford Gene Technology
  • Yikon Genomics
  • Progenesis
  • Beijing Genomics Institute（BGI）
  • Invitae Corporation
  • Invicta Genetics
  • Genea Limited

The Preimplantation Genetic Testing Market size is expected to reach USD 2587.76 Million in 2034 from USD 1021.51 Million (2025) growing at a CAGR of 10.88% during 2026-2034.

The global preimplantation genetic testing market is growing rapidly as assisted reproductive technologies become more advanced and widely adopted. Preimplantation genetic testing (PGT) is used during in vitro fertilization (IVF) to screen embryos for genetic abnormalities before implantation. This process helps improve the chances of a successful pregnancy and reduces the risk of genetic disorders.

A major driver of the market is the increasing prevalence of genetic diseases and infertility issues among couples worldwide. As awareness of genetic screening increases, more patients are opting for advanced reproductive technologies. Additionally, improvements in genomic sequencing and genetic analysis technologies have made PGT more accurate and reliable.

Looking ahead, the preimplantation genetic testing market is expected to expand significantly as reproductive medicine continues to advance. The growing demand for personalized reproductive healthcare and improved IVF success rates will support market growth. Ongoing research in genetics and reproductive biology will likely create new opportunities for advanced embryo screening technologies.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Type

• Chromosomal Abnormalities
• Aneuploidy
• X-Linked Diseases
• Single Gene Disorders
• Hla Typing
• Gender Selection
• Others

By End User

• Diagnostic Laboratories
• Hospitals
• Clinics
• Others

COMPANIES PROFILED

• Illumina Inc, Thermo Fisher Scientific Inc, Agilent Technologies Inc, PerkinElmer Inc, CooperSurgical Inc, Abbott Laboratories, Natera Inc, Takara Bio, Oxford Gene Technology, Yikon Genomics, Progenesis, Beijing Genomics Institute BGI, Invitae Corporation, Invicta Genetics, Genea Limited
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET: BY TYPE 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Type
• 4.2. Chromosomal Abnormalities Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Aneuploidy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. X-Linked Diseases Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Single Gene Disorders Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.6. Hla Typing Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.7. Gender Selection Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.8. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET: BY END USER 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast End User
• 5.2. Diagnostic Laboratories Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Hospitals Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Clinics Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET: BY REGION 2022-2034 (USD MN)

• 6.1. Regional Outlook
• 6.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.2.1 By Type
  • 6.2.2 By End User
  • 6.2.3 United States
  • 6.2.4 Canada
  • 6.2.5 Mexico
• 6.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.3.1 By Type
  • 6.3.2 By End User
  • 6.3.3 United Kingdom
  • 6.3.4 France
  • 6.3.5 Germany
  • 6.3.6 Italy
  • 6.3.7 Russia
  • 6.3.8 Rest Of Europe
• 6.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.4.1 By Type
  • 6.4.2 By End User
  • 6.4.3 India
  • 6.4.4 Japan
  • 6.4.5 South Korea
  • 6.4.6 Australia
  • 6.4.7 South East Asia
  • 6.4.8 Rest Of Asia Pacific
• 6.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.5.1 By Type
  • 6.5.2 By End User
  • 6.5.3 Brazil
  • 6.5.4 Argentina
  • 6.5.5 Peru
  • 6.5.6 Chile
  • 6.5.7 Rest of Latin America
• 6.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.6.1 By Type
  • 6.6.2 By End User
  • 6.6.3 Saudi Arabia
  • 6.6.4 UAE
  • 6.6.5 Israel
  • 6.6.6 South Africa
  • 6.6.7 Rest of the Middle East And Africa

Chapter 7. COMPETITIVE LANDSCAPE

• 7.1. Recent Developments
• 7.2. Company Categorization
• 7.3. Supply Chain & Channel Partners (based on availability)
• 7.4. Market Share & Positioning Analysis (based on availability)
• 7.5. Vendor Landscape (based on availability)
• 7.6. Strategy Mapping

Chapter 8. COMPANY PROFILES OF GLOBAL PREIMPLANTATION GENETIC TESTING INDUSTRY

• 8.1. Top Companies Market Share Analysis
• 8.2. Company Profiles
  • 8.2.1 Illumina Inc
  • 8.2.2 Thermo Fisher Scientific Inc
  • 8.2.3 Agilent Technologies Inc
  • 8.2.4 PerkinElmer Inc
  • 8.2.5 CooperSurgical Inc
  • 8.2.6 Abbott Laboratories
  • 8.2.7 Natera Inc
  • 8.2.8 Takara Bio
  • 8.2.9 Oxford Gene Technology
  • 8.2.10 Yikon Genomics
  • 8.2.11 Progenesis
  • 8.2.12 Beijing Genomics Institute (BGI)
  • 8.2.13 Invitae Corporation
  • 8.2.14 Invicta Genetics
  • 8.2.15 Genea Limited